The Salt Lake City-based drug-device developer said the patents and proprietary formulations behind the technology could prevent infection, inflammation or clotting associated with implants.
Ariste’s synthetic mesh carries two antibiotics — minocycline and rifampin — to prevent contamination by MRSA, E. coli and other bacterial pathogens associated with surgical site infections. The proprietary formulation can be applied to a variety of medical devices and incorporate any drug to address infection, restenosis, thrombosis and inflammation, the company said.
